Recognizing and Managing Adverse Events in Y-90 Radioembolization

Area of Science:

• Interventional Radiology
• Hepatobiliary Oncology
• Radiation Oncology

Background:

• Transarterial radioembolization (TARE) with yttrium-90 (Y-90) microspheres is a standard treatment for unresectable liver tumors.
• While effective, TARE can lead to specific adverse events that require careful management.

Purpose of the Study:

• To review the spectrum of toxicities associated with Y-90 radioembolization.
• To provide guidance on preventing and mitigating treatment-related complications.

Main Methods:

• Literature review of radioembolization-specific toxicities.
• Stratification of adverse events into hepatic, extrahepatic, and systemic categories.

Main Results:

• Identified common hepatic toxicities including radiation hepatitis and liver failure.
• Highlighted potential extrahepatic toxicities such as pneumonitis and gastrointestinal injury.
• Discussed systemic effects and the importance of patient selection and pre-treatment assessment.

Conclusions:

• Familiarity with Y-90 radioembolization toxicities is essential for safe patient care.
• Proactive management strategies can significantly reduce treatment-induced morbidity.
• This review serves as a resource for clinicians managing patients undergoing TARE.